secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2026-08-04T20:04:46+00:00
Accession:  0001193125-26-332752
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences Q2 net loss $45.6M; cash $353.9M; initial Ph2 data from SURF302 expected Sept 2026
--------------------------------------------------------------------------------

- Net loss of $45.6M in Q2 2026 vs $28.1M in Q2 2025; R&D expenses rose to $39.2M from $24.3M.
- Cash, cash equivalents and marketable securities of $353.9M as of June 30, 2026; runway into 2H 2028.
- Initial Ph2 data from SURF302 (dabogratinib in IR NMIBC) expected September 2026; n>40 enrolled.
- Initial Ph2 data from BEACH301 (achondroplasia) safety sentinel cohort including 5th dose level expected end of Q1 2027.
- Appointed Jonathan Day as EVP, Clinical Development; amended ATM sales agreement for up to $250M additional shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000119312526332752/0001193125-26-332752-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000119312526332752/tyra-20260804.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-332752

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer